Shuttle Pharma Nears Enrollment Milestone in Promising Glioblastoma Trial

Shuttle Pharma shares are trading higher after the company announced it is nearly halfway through patient enrollment for its Phase 2 clinical trial of Ropidoxuridine, a treatment for glioblastoma, following an expedited trial progress and promising preliminary results.